Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12 Prostatic Neoplasms 9 Neoplasms 9 Lung Neoplasms 6 Endometrial Neoplasms 6 Breast Neoplasms 6 Stomach Neoplasms 4 Oropharyngeal Neoplasms 4 Melanoma 4 Colorectal Neoplasms 4 Pathologic Complete Response 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Mouth Neoplasms 3 Leukemia, Myeloid, Acute 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Rectal Neoplasms 2 Meningioma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leiomyoma 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Hepatocellular 2 Carcinoma, Basal Cell 2 Vaginal Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Trauma, Nervous System 1

Interventions

Specimen Handling 8 pembrolizumab 7 enfortumab vedotin 7 Magnetic Resonance Spectroscopy 6 avelumab 4 Nivolumab 4 Gemcitabine 3 cabozantinib 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 Cisplatin 2 Carboplatin 2 CTLA-4 Antigen 2 Biopsy 2 vinflunine 1 tremelimumab 1 tocilizumab 1 tamibarotene 1 relatlimab 1 eribulin 1 erdafitinib 1 durvalumab 1 copanlisib 1 atezolizumab 1 Watchful Waiting 1 Standard of Care 1 Propranolol 1 Practice Guidelines as Topic 1 Plasmapheresis 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Observation × 1 year × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡